Q3 2022 vs. Q4 2022: An Analysis of Intellectus Partners, LLC's 13F Holdings

Investment management firm Intellectus Partners, LLC recently filed its 13F form with the Securities and Exchange Commission, detailing its holdings as of the end of Q4 2022. A comparison with its Q3 2022 holdings shows some interesting shifts in the firm's investment strategy. In this blog post, we'll take a closer look at some of the notable changes and what they might indicate.

Introduction:

A 13F form is a quarterly report that must be filed by institutional investment managers with assets under management of over $100 million. It lists all the positions held in their portfolio at the end of the quarter, giving investors insights into the stocks that the manager is bullish or bearish on. Intellectus Partners, LLC, a registered investment advisor, recently filed its Q4 2022 13F form, and we'll be analyzing the changes it has made since the previous quarter.

Main Body:

Abcellera Biologics (ABCL) was the largest holding of Intellectus Partners, LLC in Q3 2022, with 1,091,505 shares valued at $10,795,000. However, the firm decreased its stake in the biotech company by 20% in the following quarter, holding only 868,583 shares valued at $8,798,000. This could be a sign that the firm is trimming its exposure to the biotech sector due to regulatory uncertainty, particularly given the recent pushback against drug pricing.

Amazon.com Inc (AMZN) was another high-profile holding of Intellectus Partners, LLC in Q3, but it shed 59 shares in Q4, reducing its holdings to 99,604 shares worth $8,366,000. This decline in Amazon's value could be due to concerns about regulatory risks or a general downturn in the tech giant's performance.

Intellectus Partners, LLC increased its position in Lockheed Martin Corporation (LMT) by 3% in Q4, acquiring an additional 447 shares to bring its total holdings to 14,275 worth $6,944,000. This suggests that the firm has bullish sentiments around the defense and aerospace sector, perhaps due to geopolitical tensions and ongoing military conflicts worldwide. It's worth noting that LMT has been on a steady upward trajectory for over a year, gaining 50% in 2021.

First Trust STOXX European Sel Div ETF (FDD) was another significant position Intellectus Partners, LLC added in Q4, increasing its holdings by 22%, from 307,884 shares worth $2,882,000 in Q3 to 374,567 shares worth $4,255,000. This shift could reflect the firm's interest in a portfolio of high-dividend European stocks, as well as European equities' relative attractiveness compared to the U.S. market.

Microsoft Corp (MSFT) saw a small decrease in the number of shares held by Intellectus Partners, LLC in Q4, from 19,515 shares worth $4,545,000 to 19,245 shares worth $4,615,000, a 1.5% decline. This kind of minor shift could indicate that the firm has a moderate bearish outlook on Microsoft, even as the company continues to dominate the tech landscape.

Conclusion:

Intellectus Partners, LLC's 13F filing provides valuable insights into the strategies of this institutional investment manager, although bear in mind that these are just snapshots in time and that the firm's views may have already evolved. However, we can see some notable changes in the firm's investment strategy in Q4, such as reducing holdings in biotech and tech giants, increasing exposure to the aerospace and defense sector, and investing more in European high-dividend stocks. As always, investors should conduct their due diligence and keep an eye on relevant developments to determine whether these shifts are reflective of broader trends in the market.